Alkermes (ALKS) Capital Expenditures (QoQ) (2011 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Capital Expenditures (QoQ) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.68 Bn | 624.92 Bn | 17.26 Bn |
| 2 | AbbVie | 441.40 Bn | 434.83 Bn | 12.70 Bn |
| 3 | Merck | 365.79 Bn | 358.65 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.44 Bn | 258.75 Bn | 11.24 Bn |
| 5 | Pfizer | 158.97 Bn | 147.27 Bn | 10.94 Bn |
| 6 | Sanofi | 52.38 Bn | 45.00 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.09 Bn | 44.09 Bn | - |
| 8 | Incyte | 25.52 Bn | 20.99 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.52 Bn | 18.86 Bn | 683.80 Mn |
| 10 | Alkermes | 7.56 Bn | 6.90 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 99.17% |
| Mar 31, 2026 | 20,550.00% |
| Dec 31, 2025 | -100.12% |
| Sep 30, 2025 | 33.02% |
| Jun 30, 2025 | 28.74% |
| Mar 31, 2025 | 3.45% |
| Dec 31, 2024 | 18.35% |
| Sep 30, 2024 | 16.13% |
| Jun 30, 2024 | -14.76% |
| Mar 31, 2024 | -51.02% |
| Dec 31, 2023 | 17.83% |
| Sep 30, 2023 | 48.92% |
| Jun 30, 2023 | 41.47% |
| Mar 31, 2023 | -31.59% |
| Dec 31, 2022 | -4.26% |
| Sep 30, 2022 | 5.14% |
| Jun 30, 2022 | 27.87% |
| Mar 31, 2022 | -10.05% |
| Dec 31, 2021 | 79.95% |
| Sep 30, 2021 | -26.63% |